Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.6004/jnccn.2020.7606 | Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial |
| https://doi.org/10.2217/fon-2022-0045 | A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA -mutated breast cancer |
| https://doi.org/10.1093/ajcp/aqaa077 | Interobserver Variability in Ductal Carcinoma In Situ of the Breast |
| https://doi.org/10.1016/j.breast.2015.07.034 | Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015 |
| https://doi.org/10.1016/j.breast.2017.04.007 | New agents for endocrine resistance in breast cancer |
| https://doi.org/10.1093/annonc/mdx440.001 | Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC) |
| https://doi.org/10.3217/978-3-85125-378-8-83 | How Well Can We Learn With Standard Bci Training Approaches? A Pilot Study. |
| https://doi.org/10.1158/1538-7445.am2016-ct039 | Abstract CT039: Primary analysis of the EORTC 10041/ BIG 3-04 MINDACT study: a prospective, randomized study evaluating the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes |
| https://doi.org/10.1016/j.ejca.2021.12.030 | Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant |
| https://doi.org/10.1016/j.esmoop.2022.100772 | Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial |
| https://doi.org/10.1200/jco.2015.33.15_suppl.tps1109 | OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm). |
| https://doi.org/10.1097/cco.0b013e32834bd4c9 | HER2-overexpressing breast cancer |
| https://doi.org/10.3390/jcm10194387 | Comprehensive Review of Fluorescence Applications in Gynecology |
| https://doi.org/10.1158/0008-5472.sabcs12-s3-2 | Abstract S3-2: Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02) |
| https://doi.org/10.1200/jco.2021.39.15_suppl.tps597 | ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer. |
| https://doi.org/10.1016/j.ctrv.2014.09.004 | Small breast cancers: When and how to treat |
| https://doi.org/10.1038/onc.2015.249 | Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs |
| https://doi.org/10.1093/annonc/mdz100.003 | First report of AURORA, the breast international group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients (pts) |
| https://doi.org/10.1039/d0en01232g | Towards the development of safer by design TiO2-based photocatalytic paint: impacts and performances |
| https://doi.org/10.1038/s41467-023-42635-2 | Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials |
| https://doi.org/10.1200/jco.2019.37.15_suppl.tps598 | ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early-stage triple-negative breast cancer. |
| https://doi.org/10.1002/ijc.33385 | |
| https://doi.org/10.1136/jitc-2022-004820 | Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex |
| https://doi.org/10.1038/s41523-022-00452-8 | PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer |
| https://doi.org/10.1158/1538-7445.sabcs23-gs01-03 | Abstract GS01-03: Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial |
| https://doi.org/10.1093/jncimonographs/lgr040 | Gene Profiling Assay and Application: The Predictive Role in Primary Therapy |
| https://doi.org/10.1158/1538-7445.sabcs17-gs4-02 | Abstract GS4-02: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials |
| https://doi.org/10.1039/c9sc00341j | Model peptide for anti-sigma factor domain HHCC zinc fingers: high reactivity toward 1O2 leads to domain unfolding |
| https://doi.org/10.1007/s10549-023-07116-6 | Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium |
| https://doi.org/10.1007/s12282-023-01451-8 | Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial |
| https://doi.org/10.1016/j.esmoop.2022.100483 | Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force |
| https://doi.org/10.3389/fonc.2022.1028825 | End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO |
| https://doi.org/10.1016/j.esmoop.2025.105112 | LBA1 Adjuvant pertuzumab or placebo + trastuzumab + chemotherapy (P or Pla + T + CT) in patients (pts) with early HER2-positive operable breast cancer in APHINITY: Final analysis at 11.3 years’ median follow-up |
| https://doi.org/10.1016/j.clbc.2019.06.016 | Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer |
| https://doi.org/10.1016/j.ejca.2022.12.020 | Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer |
| https://doi.org/10.1007/s10549-020-05915-9 | Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) |
| https://doi.org/10.1093/jnci/djac096 | Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy |
| https://doi.org/10.1016/j.ejso.2023.06.005 | Current practice in assessment and management of malnutrition in surgical oncology practice – An ESSO-EYSAC snapshot analysis |
| https://doi.org/10.1016/j.esmoop.2024.103938 | Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)] |
| https://doi.org/10.1200/jco.2023.41.16_suppl.1009 | Characterization of the immune microenvironment in matched primary and metastatic breast cancer lesions from the AURORA study: BIG 14-01. |
| https://doi.org/10.1016/j.ejso.2023.107072 | Variations in the definition and perceived importance of positive resection margins in patients with colorectal cancer – an EYSAC international survey |
| https://doi.org/10.1200/jco-24-02697 | Breastfeeding After Hormone Receptor–Positive Breast Cancer: Results From the POSITIVE Trial |
| https://doi.org/10.1038/s41523-025-00768-1 | Advancing equitable access to innovation in breast cancer |
| https://doi.org/10.1016/j.annonc.2024.08.277 | 338TiP EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA) |
| https://doi.org/10.1186/s13058-024-01941-3 | Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]) |
| https://doi.org/10.1016/j.esmoop.2025.104987 | 415O Predictive factors of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in the POSITIVE trial |
| https://doi.org/10.1109/tim.2025.3587365 | Pattern Matters: The Impact of Projection Patterns on Deep Learning 3-D Profilometry |
| https://doi.org/10.1001/jamaoncol.2025.5376 | Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens |
| https://doi.org/10.1038/s41523-025-00835-7 | Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010–2021 |
| https://doi.org/10.1016/j.annonc.2025.09.022 | LBA12 5-year follow-up results from the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial |
| https://doi.org/10.1038/s41523-025-00856-2 | Novel treatment strategies and key research priorities for patients with breast cancer and central nervous system (CNS) metastases |
| https://doi.org/10.1007/s10549-008-0112-4 | Lack of prognostic significance of “classic” lobular breast carcinoma: a matched, single institution series |
| https://doi.org/10.1200/jco.2003.12.068 | Mathematics and Oncology: A Match for Life? |
| https://doi.org/10.1634/theoncologist.2012-0342 | Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience |
| https://doi.org/10.1016/j.ctrv.2011.07.005 | Chemoprevention for breast cancer |
| https://doi.org/10.3816/cbc.2008.n.035 | A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Locoregional Relapse of Breast Cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37 |
| https://doi.org/10.2217/fon.13.57 | Personalized Therapy for Breast Cancer: A Dream or a Reality? |
| https://doi.org/10.1088/0953-4075/41/5/055005 | Simple and accurate calculations on a Lagrange mesh of the hydrogen atom in a magnetic field |
| https://doi.org/10.1080/13543784.2017.1389896 | CDK4/6 blockade in breast cancer: current experience and future perspectives |
| https://doi.org/10.1007/s10549-010-0794-2 | Adjuvant!© Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer |
| https://doi.org/10.1038/446137a | Keeping faith with trial volunteers |
| https://doi.org/10.1093/jnci/djab057 | Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer |
| PERUBAHAN SOSIAL PADA KEHIDUPAN SUKU BAJO: Studi Kasus Di Kepulauan Wakatobi, Sulawesi Tenggara | |
| https://doi.org/10.1093/annonc/mdx362.065 | OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm) |
| https://doi.org/10.1016/j.ejca.2019.06.001 | The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study |
| https://doi.org/10.1016/s1470-2045(11)70117-6 | Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types |
| https://doi.org/10.1016/j.ejca.2022.01.031 | Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial |
| https://doi.org/10.3390/ijerph181910535 | Food Systems Transformation for Child Health and Well-Being: The Essential Role of Dairy |
| https://doi.org/10.1016/s1470-2045(19)30346-8 | Social networks for young patients with cancer: the time for system agility |
| https://doi.org/10.1158/0008-5472.sabcs13-ot2-6-08 | Abstract OT2-6-08: Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer – NeoPHOEBE |
| https://doi.org/10.1200/jco.2017.35.18_suppl.lba500 | APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC). |
| https://doi.org/10.2165/11595910-000000000-00000 | Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer |
| https://doi.org/10.1016/j.critrevonc.2012.08.003 | Molecular biology in breast cancer: Should molecular classifiers be assessed by conventional tools or by gene expression arrays? |
| https://doi.org/10.1158/1078-0432.ccr-21-1600 | Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis |
| https://doi.org/10.1093/annonc/mdx362.064 | PALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer |
| https://doi.org/10.1158/0008-5472.sabcs11-ot1-02-04 | OT1-02-04: Adjuvant Pertuzumab and Herceptin IN IniTial TherapY of Breast Cancer: APHINITY (BIG 4–11/BO25126/TOC4939g). |
| https://doi.org/10.1200/jco.2022.40.16_suppl.tps621 | DECRESCENDO: De-escalation of adjuvant chemotherapy in patients with HER2+/HR-/node-negative early breast cancer who achieve pCR after neoadjuvant taxane and subcutaneous dual anti-HER2 blockade. |
| https://doi.org/10.1093/annonc/mdu327.76 | Olympia, Neo-Olympia and Olympiad: Randomized Phase III Trials of Olaparib in Patients (Pts) with Breast Cancer (Bc) and a Germline Brca1/2 Mutation (Gbrcam) |
| https://doi.org/10.1200/edbk_321475 | Overcoming Barriers to Clinical Trials Cooperation: The Breast International Group Example |
| https://doi.org/10.1158/1538-7445.sabcs22-gs4-09 | Abstract GS4-09: Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14/BIG 8-13) |
| https://doi.org/10.1158/1538-7445.sabcs17-gs4-03 | Abstract GS4-03: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial |
| https://doi.org/10.1038/s41523-023-00548-9 | International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01) |
| https://doi.org/10.1200/jco.2014.32.15_suppl.508 | Efficacy of adjuvant trastuzumab (T) compared with no T for patients (pts) with HER2-positive breast cancer and tumors ≤ 2cm: A meta-analysis of the randomized trastuzumab trials. |
| https://doi.org/10.1016/j.ejca.2024.113952 | Adjuvant chemotherapy with or without atezolizumab for stage II and III triple-negative breast cancer: final analysis of the ALEXANDRA/ IMpassion030 phase 3 trial |
| https://doi.org/10.1200/jco.2018.36.15_suppl.521 | Patient (pt)-reported function and symptoms in APHINITY: A randomized comparison of chemotherapy (C) + trastuzumab (H) + placebo (Pla) versus C + H + pertuzumab (P) as adjuvant therapy in pts with HER2-positive early breast cancer (EBC). |
| https://doi.org/10.2217/fon-2022-1282 | DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer |
| https://doi.org/10.1016/j.breast.2025.104469 | Climate change impacts and sustainability integration among breast international group members |
| https://doi.org/10.1007/s10549-008-9970-z | Delivery of adjuvant sequential dose-dense FEC–Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence |
| https://doi.org/10.1080/14737140.2016.1247698 | Targeted adjuvant therapy in breast cancer |
| https://doi.org/10.1016/j.ejca.2017.10.036 | The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO |
| https://doi.org/10.1371/journal.pone.0172351 | Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA |
| https://doi.org/10.1016/j.ejca.2014.09.011 | An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: The trastuzumab case |
| https://doi.org/10.1038/s41523-017-0026-6 | The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group |
| https://doi.org/10.1653/024.101.0418 | Options for Managing Antestiopsis thunbergii (Hemiptera: Pentatomidae) and the Relationship of Bug Density to the Occurrence of Potato Taste Defect in Coffee |
| https://doi.org/10.1200/jco.19.01371 | Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial |
| https://doi.org/10.1186/bcr2209 | Are we HER-ting for innovation in neoadjuvant breast cancer trial design? |
| https://doi.org/10.1097/cco.0000000000000076 | Anticancer drug development |
| https://doi.org/10.1200/jco.2017.35.15_suppl.512 | Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial. |
| https://doi.org/10.1007/s00280-019-03826-1 | Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study |
| https://doi.org/10.1002/cam4.4449 | What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study |